
We’re excited to share more about Indonesia’s NHI system! It’s incredible to see how they implemented universal healthcare and overcame unique challenges.
These insights are based on a recent interview by Alec Hogg and Ali Ghufron Mukti but through the lens of health economics and outcomes research, and access to medicines.
Of course, no system is perfect, and Indonesia’s NHI journey reminds us of the importance of constant vigilance to address challenges like funding and corruption issues.
Thank you for sharing these important lessons!
Recent Posts

Evaluating Innovative Therapies Access in Portugal
According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...

Dutch Medicine Access Delay Impact on Patient Care in the Netherlands
Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...

Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement
An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...